The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Upgrades 2025 full-year CDMO sales and margin outlook
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
The company is addressing these observations comprehensively
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
The audit has been concluded with no major observations
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
The inspection concluded with zero Form 483 observations
Subscribe To Our Newsletter & Stay Updated
